Oncolytic virus-initiated protective immunity against prostate cancer
about
Clinical development of reovirus for cancer therapy: An oncolytic virus with immune-mediated antitumor activityPotential for Improving Potency and Specificity of Reovirus Oncolysis with Next-Generation Reovirus VariantsEmerging role of Natural killer cells in oncolytic virotherapyOncolytic viruses as anticancer vaccinesMaraba MG1 virus enhances natural killer cell function via conventional dendritic cells to reduce postoperative metastatic diseaseLymphokine-activated killer and dendritic cell carriage enhances oncolytic reovirus therapy for ovarian cancer by overcoming antibody neutralization in ascitesDeciphering the Multifaceted Relationship between Oncolytic Viruses and Natural Killer CellsOncolytic Sindbis virus targets tumors defective in the interferon response and induces significant bystander antitumor immunity in vivo.Multifaceted therapeutic targeting of ovarian peritoneal carcinomatosis through virus-induced immunomodulationImmunotherapy: shifting the balance of cell-mediated immunity and suppression in human prostate cancer.Reovirus in cancer therapy: an evidence-based reviewRandomized Phase 2 Trial of the Oncolytic Virus Pelareorep (Reolysin) in Upfront Treatment of Metastatic Pancreatic AdenocarcinomaSuppression of antiviral innate immunity by sunitinib enhances oncolytic virotherapyGemcitabine enhances the efficacy of reovirus-based oncotherapy through anti-tumour immunological mechanisms.Oncolytic vaccines.Pharmacological modulation of anti-tumor immunity induced by oncolytic viruses.Attacking Postoperative Metastases using Perioperative Oncolytic Viruses and Viral Vaccines.The oncolytic virus, pelareorep, as a novel anticancer agent: a review.Oncolytic virotherapy for urological cancers.Downregulation of key regulatory proteins in androgen dependent prostate tumor cells by oncolytic reovirus.Enhancement of antibody-dependent cell mediated cytotoxicity: a new era in cancer treatment.Intraperitoneal immunotherapy: historical perspectives and modern therapy.Two is better than one: Complementing oncolytic virotherapy with gemcitabine to potentiate antitumor immune responses.Reolysin and Histone Deacetylase Inhibition in the Treatment of Head and Neck Squamous Cell Carcinoma.NKp46 Recognizes the Sigma1 Protein of Reovirus: Implications for Reovirus-Based Cancer Therapy.Phase I/II clinical trial to assess safety and efficacy of intratumoral and subcutaneous injection of HVJ-E in castration-resistant prostate cancer patients.Newly recruited CD11b+, GR-1+, Ly6C(high) myeloid cells augment tumor-associated immunosuppression immediately following the therapeutic administration of oncolytic reovirus.Cytokine-induced killer cell delivery enhances the antitumor activity of oncolytic reovirus.Panorama from the oncolytic virotherapy summit.Capitalizing on Cancer Specific Replication: Oncolytic Viruses as a Versatile Platform for the Enhancement of Cancer Immunotherapy Strategies.Oncolytic Viruses Partner With T-Cell Therapy for Solid Tumor Treatment
P2860
Q26750568-12221383-1729-4538-A5FF-5EE5A3AEA12CQ26775033-CDF44EBA-338B-4B59-AFA3-2CE86C5863EBQ27025330-3F5237AC-72F3-4EEA-A5CB-5905963AF18AQ27025600-2B3AE66C-85F3-4152-8A48-2DD1F851AA25Q33870670-5F88F963-136E-4CD5-83AC-B8AD3412768FQ35061974-C4EB18DF-7F82-457A-989B-7A32B2AE4F1AQ35687743-E2381A7D-CFAE-4156-8673-46A623BE63A1Q35750051-AA7F4EB7-6864-4999-9233-F7066F530FC5Q36673709-426661EA-DC17-45D6-90BF-26AA32893A0CQ37017085-2C23440E-9702-42A5-BBEA-31A2CF2F714DQ37031909-1F63938E-1190-43B9-8507-55ED138B2EF9Q37043514-3480E8CB-A9D1-4A5D-B2E3-0047AC1DB320Q37181377-4C0179B7-5D23-415D-A24D-76BE5A483715Q37459636-61DDD863-B4DE-44F3-AAB9-784D26B5D305Q38152474-884A6680-4986-4B57-8F61-A41E82153F9CQ38237657-0064324F-25D2-41C9-A442-B46F39BC2571Q38243811-5FBDF5C9-FC17-4DA5-8BC1-55E8023EEEC8Q38360781-D07C9EEC-82D4-4871-A6C1-F9FB4C70CB7EQ38842126-D57F2D7F-20A8-40C2-B94D-CFCB75C8C267Q38844346-3AA9D5CB-840B-4BF3-8178-7DFEBD59E75FQ38912287-CED64723-D8B8-4676-911E-84D2DB429F4CQ39005211-66415AF3-2B62-4A32-9897-6DA395BBAA90Q39244891-F9D2AA3C-E123-416E-8E49-570E0AE87202Q40081751-9622709C-8099-4ED4-9295-7D43C4F1D7C3Q40115977-8DA1678D-DD74-4C25-82BA-570FB6EEB1D1Q40204247-5CF143D1-C829-4D1E-A314-A2D6B518183DQ41137180-A996776B-0418-4D11-B042-0E7385AD61EAQ41702562-73889F7A-2A50-419F-B998-CFA2DE690673Q42934744-586A38DD-9C49-4519-8A78-D1A895AD32C5Q50865520-30FC7961-DCF4-421C-B5A2-8C5513DE33C5Q57300017-8DB7E876-6EEF-4DE1-B7C9-E02731B4F6FD
P2860
Oncolytic virus-initiated protective immunity against prostate cancer
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Oncolytic virus-initiated protective immunity against prostate cancer
@en
Oncolytic virus-initiated protective immunity against prostate cancer.
@nl
type
label
Oncolytic virus-initiated protective immunity against prostate cancer
@en
Oncolytic virus-initiated protective immunity against prostate cancer.
@nl
prefLabel
Oncolytic virus-initiated protective immunity against prostate cancer
@en
Oncolytic virus-initiated protective immunity against prostate cancer.
@nl
P2093
P2860
P356
P1433
P1476
Oncolytic virus-initiated protective immunity against prostate cancer
@en
P2093
Katy A Garant
Paola Marcato
Patrick W K Lee
Shashi A Gujar
P2860
P304
P356
10.1038/MT.2010.297
P577
2011-01-18T00:00:00Z